PHRX 4041 Immuno - Drug Therapy in Transplantation

0.0(0)
studied byStudied by 0 people
0.0(0)
full-widthCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/71

encourage image

There's no tags or description

Looks like no tags are added yet.

Study Analytics
Name
Mastery
Learn
Test
Matching
Spaced

No study sessions yet.

72 Terms

1
New cards

which 3 transplants can have a live donor?

- lungs

- liver

- kidney

2
New cards

what are the most common causes of kidney transplants?

- diabetes

- hypertension

3
New cards

what is the most common cause of liver transplants?

hepatitis C

4
New cards

what are the most common causes of heart transplants?

- end stage heart failure

- hereditary condiions

- previous infection causing cardiomyopathy

- drugs

5
New cards

what are the most common causes of lung transplants?

- cystic fibrosis

- COPD

- pulmonary fibrosis

- pulmonary hypertension

6
New cards

who decides how to allocate organs?

UNOS

7
New cards

describe living donor organ donations

can either be living related or living unrelated

8
New cards

describe deceased donor organ donations

- brain death

- cardiac death; but has inferior outcomes

9
New cards

what are 3 risk factors for transplant rejection?

- sensitization (previous transplant, pregnancy, blood transfusions)

- VAD

- African american

10
New cards

overall, describe signal 1 of T cell activation during a transplant rejection response

- antigen recognition

- activates calcenurin

- turn on NFAR

- Il-2 production

11
New cards

overall, describe signal 2 of T cell activation during a transplant rejection response

- costimulation between CD28 and CD80/86

- full activation of T cell

12
New cards

overall, describe signal 3 of T cell activation during a transplant rejection response

- IL-2 binding

- mTor activated

- T cell proliferation

13
New cards

what are 3 goals of induction therapy?

- reduce incidence of acute rejection in 1st year

- treat and prevent delayed graft function

- delay initiation of CNI

14
New cards

which induction therapies are considered polyclonal?

antithymocyte globulin

15
New cards

which induction therapies are considered monoclonal?

- basiliximab

- alemtuzumab

16
New cards

which induction therapies are considered T cell depleting?

- anti thymocyte globulin

- alemtuzumab

17
New cards

which induction therapies are considered T cell NON depleting?

basiliximab

18
New cards

basiliximab brand name?

Simulect

19
New cards

describe MOA of basiliximab

binds to alpha chain of IL-2 receptor complex CD25 and inhibits IL-2 binding

20
New cards

describe ADEs seen with basiliximab

relatively few side effects

21
New cards

what 2 formulations of anti-thymocyte globulin are available? what are the differences

- thymoglobulin = rabbit derived

- atgam = equine

22
New cards

describe MOA of anti-thymocyte globulin

T cell depletion via complement depend cell lysis

23
New cards

what ADEs are seen with anti-thymocyte globulin?

- cytokine release syndrome

- serum sickness

- leukopenia and thrombosis

24
New cards

does anti-thymocyte globulin require premedication?

yes, required 30 mins prior to infusion

- APAP

- diphenhydramine

- steroids

25
New cards

compare thymoglobulin and atgam

- thymoglobulin is better for pt and graft survival

- atgam rarely used for solid organ transplant, high rates of batch inconsistency

26
New cards

alemtuzumab brand name?

campath

27
New cards

describe the MOA of

alemtuzumab

binds to CD52 on the surface of B and T cells causing apoptosis

28
New cards

describe ADEs seen with alemtuzumab

- infusion related reactions, better tolerated with SC admin

- IV admin is associated with cytokine release syndrome

- leukopenia and thrombocytopenia

29
New cards

when choosing an induction agent, when would you want to chose a T cell non depleting agent? (basiliximab)

- low risk of rejection = living donor, older age

- HIV, HepC

- liver transplant

30
New cards

when choosing an induction agent, when would you want to chose a T cell depleting agent? (antithymocyte globulin, alemtuzumab)

high risk of rejection:

- deceased donor

- comorbidies

- African american

- previous transplant

- younger age

31
New cards

what are 6 goals of maintenance therapy?

- reduce incidence of acute rejection

- prolong graft survival

- balacne infection risk

- minimize side effects

- facilitate adherence

32
New cards

what 2 classes of meds are used as main maintenance immunosuppression meds?

- CNIs (backbone meds)

- co stimulatory blockers

33
New cards

what 2 meds are CNIs?

- cyclosporine

- tacrolimus

34
New cards

cyclosporine brand names?

modified = neoral and gengraf

non modified = sand immune

- they are NOT interchangeable

35
New cards

tacrolimus brand names? which formulation is preferred?

- prograf

- astragraf XL

- envarsus XR

want to use ER forms = less ADES

36
New cards

describe MOA of CNIs

- work on signal 1

- form a complex that binds with calcenurin preventing expression of T cell activators

37
New cards

what are CNIs substrates of?

CYP3A4 and p-gp

38
New cards

what 2 ADEs are seen specifically with tacrolimus?

- pancreatic islet toxicity (diabetes)

- alopecia

39
New cards

what 5 ADEs are seen with both CNIs (tacrolimus and cyclosporine)?

- nephrotoxicity

- neurotoxicity

- hypertension

- hyperkalemia

- hypomagnesemia

40
New cards

what 3 ADEs are seen specifically with cyclosporine?

- hirsutism (hair growth)

- gingival hyperplasia

- hyperlipidemia

41
New cards

describe therapeutic drug monitoring for CNIs

- monitoring based on trough levels

- should measure levels 30 mins prior to next dose

- do not take CNI prior to blood draw

42
New cards

what trough levels are seen with tacrolimus?

5-15 ng/ml

43
New cards

what trough levels are seen with cyclosporine?

50-300 ng/mL

44
New cards

what drug is a co-stimulatiory blocker?

belatacept, acts on signal 2

45
New cards

belatacept brand name?

nulojix

46
New cards

how does belatacept work?

- binds to surface receptors CD80 and CD86 (B7 and B7-2) on antigen presenting cells

- inhibits interaction between APCs and T cells needed for T cell activation.

47
New cards

what is belatacept approved for?

only approved for kidney transplants

48
New cards

what BBW is seen with belatacept? what does this mean?

- post transplant lyphoproliferative disorder

- can only be used in Epstein Barr virus positive pts

49
New cards

what ADEs are seen with belatacept?

considered minimal compared to others

- anemia

- headache

- nausea, vomiting and diarrhea

50
New cards

compare belatacept to CNIS in terms of kidney function

belatacept shows much better kidney function over time

51
New cards

what 3 drug classes are often used as add on agents for maintenance immunosuppression?

- antiproliferatuve

- mTORi

- corticosteroids

52
New cards

what 2 drugs are considered to be anti proliferative/antimetabolites

- myophenolate

- axathioprine

53
New cards

what 2 formulations of mycophenolate exist? brand names?

- mycophenolate mofetil = cellcept

- mycophenolate sodium = myfortic

54
New cards

describe the MOA of mycophenolate

inhibits IMPDH and prevents de novo protein synthesis in lymphocytes

55
New cards

describe dosing conversions between mycophenolate agents

- cellcept 1000 mg = myfortic 720 mg

- cellcept IV to PO = 1:1

56
New cards

what 3 ADEs are seen with mycophenolate agents?

- GI (most common)

- leukopenia, thrombocytopenia, enamia

- teratogenic (has REMs)

57
New cards

describe the REMS program seen with mycophenolate

- exists since mycophenolate is teratogenic

- evidence of 1st trimester pregnancy loss and congenital malformations

- must provide education and contraception counseling

58
New cards

how should pregnancy be planned when using mycophenolate?

- stop medication for 6 weeks

- switch to alt med

59
New cards

azathioprine brand names?

- imuran

- azasan

- AZA

60
New cards

describe MOA of azathioprine

- incorperates into cellular DNA interfering with RNA synthesis and metabolism

- inhibits gene replication

- inhibits proliferation of promyelocytes in marrow

61
New cards

what mammalian target of rapamycin (mTORi) drugs are used for maintenance therapy?

- sirolimus

- everolimus

62
New cards

sirolimus brand name?

rapamune

63
New cards

everolimus brand name?

Zortress

64
New cards

describe the MOA of mTORis

- binds to mTOR which results in cell cycle arrest at G1

- inhibits proliferation of many cell line

65
New cards

what monitoring is required with mTORis?

monitoring for dose/trough levels

66
New cards

what are mTORis substrates of?

CYP3A4

67
New cards

when are mTORis considered for maintenance therapy?

- history of cancer

- intolerance to CNIs

- history of viral infections; BK virus

68
New cards

what overall consideration is taken with ADEs of mTORis?

have ALOT of ADEs, hard to tolerate

69
New cards

what corticosteroids are used as add on maintenance therapy?

- prednisone

- prednisolone

- methylprednisone

70
New cards

describe MOA of glucocorticoids

acute effects:

- decreased vasodilation and capillary permeability

- decreased leukocyte migration

upon binding to GRs:

= inhibit NFKB

- decrease pro inflammatory cytokines

- reduced B and T cells

- reduced APCs

71
New cards

what OTC meds should especially be avoided after transplant?

NSAIDS

72
New cards

what are 5 OTC meds that are safe after transplant?

- APAP

- diphenhydramine

- guafenisen

- colace

- Senna